Drugs | FDA
Skip to FDA Search
Skip to in this section menu
Skip to footer links
In this section
Topic Paragraphs
FDA launches new adverse event look-up tool
As part of a commitment to modernization and transparency, the agency is offering direct access to product safety data. All submitted reports are now consolidated into one streamlined, user-friendly dashboard for scientists, researchers, and the public.
Consumer Contact Information
Drug Alerts and Statements
What's New Related to Drugs
Drugs@FDA
Find information about most FDA-approved prescription, generic, and over-the-counter drug products.
Drug Shortages
Find information about drug shortages caused by manufacturing and quality problems, delays, and discontinuations.
National Drug Code Directory Search
Find information about finished drug products, unfinished drugs, and compounded drug products.
Orange Book
The Orange Book identifies drug products approved by FDA on the basis of safety and effectiveness.
Call-to-action encourages new uses for testosterone replacement therapy
Agency promotes exploring low libido treatments for men with hypogonadism
New treatment targets rare kidney disease for the first time
Therapy now includes children eight and older with FSGS without nephrotic syndrome
Pictured are some of the hyaluronic acid products found to contain hidden drug ingredients. Using these unapproved products can lead to severe health issues and hospitalization.
Hidden ingredients pose risks in some hyaluronic acid products
Using the unapproved products can lead to severe health issues and hospitalization
Drug Information, Safety, and Availability
Medication Guides, Drug Safety Communications, Shortages, Recalls
Drug Approvals and Databases
Drugs@FDA, Orange Book, National Drug Code, Recent drug approvals
Drug Development and Review Process
Drug applications, submissions, manufacturing, and small business help
Guidance, Compliance, and Regulatory Information
Guidances, warning letters, drug compounding, international information, registration and listing
Regulatory Science and Research
CDER research programs, initiatives, and resources
Emergency Preparedness
Prepare and respond to natural disasters, nuclear and chemical attacks
Updates, News, Events, and Training
Recent approvals, meetings, workshops, blogs, podcasts, stay connected
About the Center for Drug Evaluation and Research (CDER)
Our role, mission, organization, history, leadership, job openings
Center
Webcast
Apr 29
FDA Webinar on the RCT-DUPLICATE Initiative: Emulating Randomized Clinical Trials with Non-Randomized Real-World Data Studies
Advisory Committee Meeting
Apr 30
April 30, 2026: Meeting of the Oncologic Drugs Advisory Committee Meeting Announcement
More Events
Biosimilars Education Initiative
Learn how biosimilars are safe and effective treatment options
Opioids
Reducing the impact of opioid misuse and abuse
Generics
Ensuring access to safe, affordable, and effective generic drugs
Warning Letters
Warning and Notice of Violation Letters to Pharmaceutical Companies
Guidances
FDA's current thinking on drug development and review activities
Drug Shortages
Search the database, learn about root causes and potential solutions
Resources
Information for consumers, health professionals, and industry
Disposal of Unused Medicines
Learn how to properly get rid of unused or expired medication
Division of Drug Information
U.S. Food and Drug Administration
10903 New Hampshire Avenue
Building 51, Room 1109
Silver Spring, MD 20993
druginfo@fda.hhs.gov
Toll Free
(855) 543-3784
(301) 796-3400
Hours Available
Center for Drug Evaluation and Research (CDER)
Paragraph Header (Column 2)
FOR UPDATES ON X FOLLOW
@FDA_Drug_Info
Your source for the latest drug information.
Know the moment it happens.
Back to
Top